Pharmaceuticals

Breakout Performance: Stock rose by 8.5% following the U.S. exemption of Indian pharmaceutical products from new tariffs. Growth Drivers: Strong export performance, particularly to the U.S., and a robust product pipeline. Long-Term Potential: With global demand for affordable generics and biosimilars, Gland Pharma is well-positioned for sustained growth.